Head-and-neck squamous cell carcinomas (SCCs) are malignancy with propensity mostly for the locoregional spread. Most frequent sites of distant metastases include lung, bone, liver, and adrenal. Distant metastases to nonregional lymph nodes without visceral involvement from oropharyngeal cancer are extremely rare. To the authors' knowledge, this is the first case reported where a male presented with SCC of the base of tongue with widespread nodal metastases without any visceral involvement as primary presentation.
INTRODUCTION
The management of the neck in squamous-cell carcinoma (SCC) of the head and neck is based on the predictable pattern of lymphatic spread of disease to the cervical lymph nodes. Unpredictable spread hardly occurs. 1 Metastases from the head-and-neck carcinomas to lymph nodes below the clavicular region have been reported very infrequently in the literature. This index case is the first reported case where the axillary, mediastinal, retroperitoneal, and inguinal nodes were involved as the primary presentation of the patient with SCC of the base of the tongue.
CASE REPORT
An otherwise well, 45-year-old male, a chronic smoker presented with 3 months history of swelling on his left side of the neck. On clinical examination, he was found to have an abnormal growth in the base of tongue (more on the left side) involving anterior tonsillar pillar with extension into the left tonsil and valleculae and the lesion measured 5 cm in maximum diameter. He had multiple enlarged bilateral cervical nodes, all measuring <6 cm in diameter. This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.
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In view of Stage IV disease, he was started on palliative chemotherapy with paclitaxel and carboplatin.
DISCUSSION
The predictable pattern of lymphatic metastasis based on tumor histology and site of origin has been well-documented for most head-and-neck cancers. 2 These cancers typically present with local symptoms; distant metastases are relatively uncommon. 3 Alavi et al. reviewed 342 patients with mucosal head-and-neck SCCs (HNSCC), and 47 (13.7%) had distant metastases. Five patients (1.5%) had metastases to distant lymph nodes (axilla, inguinal, and presternal). 3 Metastasis of SCC of the head-and-neck region to distant lymph nodes has been reported very infrequently in the literature. An exhaustive English literature search suggests this to be the first reported case of carcinoma of the base of the tongue with disseminated lymph node metastases. Strong prognostic indicators that predict the development of distant metastases are the presence and number of lymph node metastases in the neck and extranodal spread. Much studies have invested into the understanding of lymphatic dissemination of cancer. Possible explanation for this unusual location of lymphatic metastases is blockage of lymph nodes as a result of surgical manipulation or radiotherapy or metastasis from a second primary tumor. Patients who underwent tracheostomy or with parastomal recurrences are at risk of axillary lymph node metastasis due to lymphatic connections between the skin and soft tissues at the level of manubrium to the transverse cervical chain as well as to axillary lymph nodes. 4, 5 Hence, it makes our case unique, as the disseminated lymph node metastases were found in the primary setting with no history of surgery, radiotherapy, tracheostomy, recurrence, or other synchronous or metachronous malignancies. Hence, considering existing evidence, we believe either there was lymphatic spillage owing to local blockades by heavy tumor burden or there is another hidden plausible theory, yet to be discovered. Once distant metastases are detected, patients have a very poor prognosis. The time interval between the diagnosis of distant metastasis and death is <2 years in >90% of such cases. 6 The optimal management of this type of distant lymphatic metastasis remains poorly defined because of an insufficient number of patients reported in the literature. Some drugs have been demonstrated in clinical trials to have activity in HNSCCs and the list is well-summarized in prior reviews. 7, 8 The most commonly used include methotrexate, cisplatin, carboplatin, 5-FU, paclitaxel, and docetaxel, with reported major response rates ranging from 15% to 42%. Cetuximab in combination with platinum-based combination chemotherapy is superior to chemotherapy alone in patients with recurrent or metastatic HNSCC, and it is recommended to improve overall survival, progression-free survival, and response rate. 9 Immunotherapy represents an attractive treatment strategy for recurrent or metastatic HNSCC with promising preliminary results. 10 
